Navigation Links
VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis
Date:10/7/2010

SAN DIEGO and SEATTLE, Oct. 7 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) candidates for the treatment of cancer, respiratory and inflammatory diseases, announced today results from its randomized, placebo controlled clinical trial evaluating VTX-1463 for the treatment of allergic rhinitis. The results demonstrated that VTX-1463 significantly improved allergy symptoms based on Total Nasal Symptom Scores (TNSS) compared to placebo (p=0.012). TNSS is the standard endpoint used in allergy trials that takes into account nasal congestion, itching, sneezing and rhinorrhea. VTX-1463 is a selective TLR8 agonist that is delivered intranasally on a weekly basis.

"It's encouraging to see such robust results from this new selective TLR8 agonist," said Friedrich Horak, M.D., Professor of the Medical University Vienna and Vienna Challenge Chamber (VCC) in Vienna, Austria, and principal investigator of this study. "Given that allergic rhinitis impacts a substantial portion of the overall population, a potential drug like VTX-1463 that is administered intranasally once a week could provide an important advantage for patients."

The clinical trial assessed safety and efficacy of VTX-1463 in a randomized, placebo controlled study in 80 patients with confirmed allergy to grass pollen in the Vienna Challenge Chamber. VTX-1463 was evaluated as a stand-alone agent administered once-weekly in four doses intranasally. Further details of the trial and results will be presented at an upcoming scientific meeting.

"These data provide clinical proof-of-concept for further development of VTX-1463 in allergic rhinitis as well as the rationale to potentially explore other allergic indications," said Robert Hershberg, M.D., Ph.D., Co-founder and Chief Medical Officer at VentiRx. "The VTX-1463 data combined with recent data generated with VTX-2337 in oncology validates TLR8 as an important and relevant target in human diseases."

"VTX-1463 is the first TLR8 agonist for the treatment of allergies," said Michael Kamdar, Co-Founder and Chief Business Officer at VentiRx. "Given the potential for weekly dosing that is allergen independent, VTX-1463's emerging product profile is markedly different from existing treatments and may be very beneficial for allergic patients."

About VCC

The Vienna Challenge Chamber is an Allergen Exposure Chamber covered by Canadian Patent No. 2,416,328, EU Patent No. 1,335,750 and US patent pending.

About VentiRx Pharmaceuticals

VentiRx Pharmaceuticals Inc. is a biopharmaceutical company committed to the development and commercialization of novel medicines for the treatment of cancer, respiratory and inflammatory diseases. The Company's initial focus is on developing small molecule TLR-based product candidates for oncology and allergy. VentiRx is a privately held organization with operations in San Diego and Seattle. For additional information, please visit www.ventirx.com.


'/>"/>
SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FierceBiotech Names VentiRx Pharmaceuticals as One of the Fierce 15 Biotech Companies of 2010
2. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
3. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
4. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
5. Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel
6. ISTA Pharmaceuticals Reports Positive Preliminary Results from its Phase 1/2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
7. MAP Pharmaceuticals Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
8. Savient Pharmaceuticals Announces Dismissal of Class Action Lawsuit
9. Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results
10. Transcept Pharmaceuticals to Present at BIO Investor Forum
11. MAP Pharmaceuticals, Inc. Announces Pricing of Underwritten Registered Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... 24, 2016 According to a ... (Standard Pen Needles, Safety Pen Needles), Needle Length (4mm, ... Hormone), Mode of Purchase (Retail, Non-Retail) - Trends & ... studies the market for the forecast period of 2016 ... 2.81 Billion by 2021 from USD 1.65 Billion in ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
(Date:6/24/2016)... ... 2016 , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The ... members that have been wounded in battle and their families. Venture Construction Group is ...
Breaking Medicine News(10 mins):